Skip to main content
Lotties
1 - src: /sites/elevidyshcp/files/2024-08/ELE-HCP-2.0-Crecent-7-001.json / styles: top: -290px;left: -280px;width: 592px;height: 751px; / flip x: 0
2 - src: /sites/elevidyshcp/files/2024-08/ELE-HCP-1.0-2.0-Crecent-8-001_0.json / styles: top: 890px;right: -390px;width: 610px;height: 1841px;transform: scaleX(-1); / flip x: 1

Evaluated in a robust clinical trial program with a broad patient population1*

ELEVIDYS was evaluated in multiple clinical trials that included a broad patient population of more than 200 individuals. Clinical trials are ongoing to verify long-term efficacy and safety data.1,24-27

* All patients were on a stable dose of cortocosteroids prior to ELEVIDYS infusion.

KEY DEMOGRAPHICS1

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 1 (Part 1)

ELEVIDYS

n=20

Placebo

n=21

65%

81%

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

STUDY 2†

ELEVIDYS

N=48

77%

7.7

(3.2 to 20.2)

30.1

(12.5 to 80.1)

STUDY 3

ELEVIDYS

n=63

Placebo

n=62

78%

74%

6.0

(4.1 to 7.9)

6.1

(4.0 to 7.9)

21.3

(13.5 to 38.5)

22.4

(14.4 to 41.6)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 1 (Part 1)

ELEVIDYS

n=20

Placebo

n=21

65%

81%

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 2*

ELEVIDYS

N=48

77%

7.7

(3.2 to 20.2)

30.1

(12.5 to 80.1)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 3

ELEVIDYS

n=63

Placebo

n=62

78%

74%

6.0

(4.1 to 7.9)

6.1

(4.0 to 7.9)

21.3

(13.5 to 38.5)

22.4

(14.4 to 41.6)

† Cohorts 1, 2, 4, and 5a included 40 ambulatory patients; Cohorts 3 and 5b included 8 non-ambulatory patients.
Patients with moderate to severe left ventricular ejection fracture (LVEF) impairment have not been studied in clinical trials with ELEVIDYS.

see clinical trial results
Study 11

Completed, multicenter trial in 41 ambulatory males aged 4 to 7 years:

  • Part 1: 48-week, double-blind, placebo-controlled randomized period; randomization stratified by age (4 to 5 years vs 6 to 7 years)
  • Part 2: 48-week, double-blind, placebo-controlled crossover‡ period after Part 1
PRIMARY OBJECTIVES
  • ELEVIDYS micro-dystrophin expression in skeletal muscle, as measured by western blot
  • Motor function, as measured by NSAA total score
KEY BASELINE CHARACTERISTICS (PART 1)
Characteristic

All

N=41

ELEVIDYS

n=20

Placebo

n=21

Mean age, years (range)

6.3

(4.3 to 7.9)

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

Mean weight, kg (range)

22.4

(15.0 to 34.5)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

Mean NSAA total score (range)

21.2

(13 to 29)

19.8

(13 to 26)

22.6

(15 to 29)

Mean TTR from floor, seconds (range)

4.3

(2.7 to 10.4)

5.1

(3.2 to 10.4)

3.6

(2.7 to 4.8)

‡ In the crossover period, patients randomized to placebo in Part 1 received ELEVIDYS in Part 2, and patients randomized to ELEVIDYS in Part 1 received placebo in Part 2. 
NSAA=North Star Ambulatory Assessment; TTR=time to rise.

Study 21

Ongoing, open-label, multicenter trial in 40 ambulatory males (cohorts 1, 2, 4, and 5a) and 8 non-ambulatory males (cohorts 3 and 5b)

PRIMARY OBJECTIVE
  • ELEVIDYS micro-dystrophin in skeletal muscles, as measured by western blot
KEY BASELINE CHARACTERISTICS
Characteristic

Cohort 1

n=20

Cohort 2

n=7

Cohort 3

n=6

Cohort 4

n=7

Cohort 5a

n=6

Cohort 5b

n=2

Mean age, years (range)

5.8

(4.4 to 7.9)

10.1

(8.0 to 12.1)

15.3

(9.9 to 20.2)

3.5

(3.2 to 3.9)

6.7

(4.7 to 8.6)

13.4

(12.3 to 14.6)

Mean weight, kg (range)

21.2

(15.2 to 33.1)

37.1

(28.0 to 50.5)

59.9

(36.1 to 80.1)

15.2

(12.5 to 16.5)

32.1

(19.1 to 47.4)

51.2

(43.4 to 59.0)

Mean NSAA total score (range)

22.1

(18 to 26)

20.7

(17 to 26)

NA§

12.9

(11 to 17)

22.5

(18 to 30)

NA§

Mean TTR from floor, seconds (range)

4.2

(2.4 to 8.2)

5.9

(3.8 to 9.7)

NA§

5.2

(3.8 to 6.7)

4.6

(2.5 to 7.7)

NA§

Characteristic

Cohort 1

n=20

Cohort 2

n=7

Cohort 3

n=6

Mean age, years (range)

5.8

(4.4 to 7.9)

10.1

(8.0 to 12.1)

15.3

(9.9 to 20.2)

Mean weight, kg (range)

21.2

(15.2 to 33.1)

37.1

(28.0 to 50.5)

59.9

(36.1 to 80.1)

Mean NSAA total score (range)

22.1

(18 to 26)

20.7

(17 to 26)

NA§

Mean TTR from floor, seconds (range)

4.2

(2.4 to 8.2)

5.9

(3.8 to 9.7)

NA§

Characteristic

Cohort 4

n=7

Cohort 5a

n=6

Cohort 5b

n=2

Mean age, years (range)

3.5

(3.2 to 3.9)

6.7

(4.7 to 8.6)

13.4

(12.3 to 14.6)

Mean weight, kg (range)

15.2

(12.5 to 16.5)

32.1

(19.1 to 47.4)

51.2

(43.4 to 59.0)

Mean NSAA total score (range)

12.9

(11 to 17)

22.5

(18 to 30)

NA§

Mean TTR from floor, seconds (range)

5.2

(3.8 to 6.7)

4.6

(2.5 to 7.7)

NA§

§ Not evaluated in non-ambulatory patients. 
NSAA=North Star Ambulatory Assessment; TTR=time to rise.

Study 31,2,28

Ongoing, randomized, multicenter, double-blind, placebo-controlled trial in 125 ambulatory males aged 4 to 7 years

PRIMARY OBJECTIVE
  • Motor function, as measured by NSAA total score
KEY SECONDARY OBJECTIVES
  • ELEVIDYS micro-dystrophin expression in skeletal muscle, as measured by western blot
  • Motor function, as measured by:
    • TTR from floor
    • Time of 10MWR
ADDITIONAL OBJECTIVES
  • Motor function, as measured by:
    • Time of 100MWR
    • Time to ascend 4 steps
KEY BASELINE CHARACTERISTICS
Characteristic

ELEVIDYS

n=63

Placebo

n=62

Mean age, years (range)
  4-5 years, n (%)
  6-7 years, n (%)

6.0 (4.1 to 7.9)
30 (47.6)
33 (52.4)

6.1 (4.0 to 7.9)
29 (46.8)
33 (53.2)

Mean weight, kg (range)

21.3 (13.5 to 38.5)

22.4 (14.4 to 41.6)

Mean time since corticosteroid treatment started, years (range)

1.07 (0.23 to 6.17)

0.97 (0.24 to 4.01)

PRIMARY OBJECTIVES
Mean NSAA total score, points (range)

23.10 (14 to 32)

22.82 (15.5 to 30)

KEY SECONDARY OBJECTIVES
Mean TTR from floor, seconds (range)

3.52 (1.9 to 5.8)

3.60 (2.3 to 5)

Mean 10MWR, seconds (range)

4.82 (3.2 to 6.9)

4.92 (3.7 to 7)

ADDITIONAL OBJECTIVES
Mean 100MWR, seconds (range)

60.67 (38.0 to 129.2)

63.01 (38.7 to 118.1)

Mean time to ascend 4 steps, seconds (range)

3.17 (1.6 to 7.1)

3.37 (1.5 to 7.1)

MWR=meter walk/run; NSAA=North Star Ambulatory Assessment; TTR=time to rise.

see clinical trial results

References:

  • 1. ELEVIDYS. Prescribing information. Sarepta Therapeutics, Inc; November 2025
  • 2. Data on file. Sarepta Therapeutics, Inc. Cambridge, MA.
  • 24. Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762. doi:10.3389/fcell.2023.1167762
  • 25. A long-term follow-up study of participants who received delandistrogene moxeparvovec (SRP-9001) in a previous clinical study (EXPEDITION). Clinicaltrials.gov identifier: NCT05967351. Updated January 17, 2025. Accessed January 19, 2026. https://clinicaltrials.gov/study/NCT05967351
  • 26. A gene transfer therapy study to evaluate the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in non-ambulatory and ambulatory participants with Duchenne muscular dystrophy (DMD) (ENVISION). Clinicaltrials.gov identifier: NCT05881408. Updated June 22, 2025. Accessed January 19, 2026. https://clinicaltrials.gov/study/NCT05881408
  • 27. An observational study comparing delandistrogene moxeparvovec with standard of care in participants with Duchenne muscular dystrophy (ENDURE). Clinicaltrials.gov identifier: NCT06270719. Updated December 2, 2025. Accessed January 19, 2026. https://clinicaltrials.gov/study/NCT06270719
  • 28. Mendell JR, Muntoni, F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31(1):332-341. https://doi.org/10.1038/s41591-024-03304-z

Indication

ELEVIDYS is indicated for the treatment of ambulatory patients 4 years of age and older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.

Limitations of Use
ELEVIDYS is not recommended in patients with:

  • Preexisting liver impairment (defined as gamma-glutamyl transferase [GGT] > 2 x upper limit of normal or total bilirubin > the upper limit of normal not due to Gilbert's syndrome) or active hepatic viral infection due to the high risk of acute serious liver injury and acute liver failure.
  • Recent vaccination (within 4 weeks of treatment) due to immunogenicity and potential safety concerns.
  • Active or recent (within 4 weeks) infections due to safety concerns.

Please see full Prescribing Information, including Boxed Warning, and Medication Guide.

Important Safety Information, including Boxed Warning

BOXED WARNING: Acute Serious Liver Injury and Acute Liver Failure

Acute serious liver injury, including life-threatening and fatal acute liver failure, has occurred.
Patients with preexisting liver impairment may be at higher risk. 

Prior to infusion, assess liver function by clinical examination and laboratory testing. Administer systemic corticosteroids before and after ELEVIDYS infusion. Continue to monitor liver function weekly for the first 3 months after infusion and continue until results are unremarkable. 

Instruct patients to maintain proximity to an appropriate healthcare facility, as determined by the healthcare provider, for at least 2 months following ELEVIDYS infusion.

Obtain prompt consultation with a specialist (e.g., gastroenterologist or hepatologist) if acute serious liver injury or impending acute liver failure is suspected.

CONTRAINDICATION
ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9, including a deletion of any portion or the entirety of these exons, in the DMD gene. 

WARNINGS AND PRECAUTIONS
Acute Serious Liver Injury and Acute Liver Failure
See Boxed Warning.

  • Acute serious liver injury marked by elevations of liver enzymes (e.g., GGT, ALT) and total bilirubin and acute liver failure has occurred with ELEVIDYS. Onset of the liver injury typically begins within 8 weeks of ELEVIDYS administration. In non-ambulatory patients treated with ELEVIDYS, acute liver failure with fatal outcome has occurred in the clinical and post-marketing settings.
  • Life-threatening mesenteric vein thrombosis, complicated by bowel ischemia and necrosis, and portal hypertension have been reported following acute liver injury associated with ELEVIDYS in a non-ambulatory patient.
  • Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury or acute liver failure. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled.
  • Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated.

Serious infections

  • Increased susceptibility to serious infections may occur due to concomitant administration of corticosteroid regimen and additional immunosuppressants, and ELEVIDYS. Serious respiratory infections, including with fatal outcomes, have occurred in patients taking immunosuppressant corticosteroids required for ELEVIDYS administration.
  • Monitor patients for signs and symptoms of infection before and after ELEVIDYS administration and treat appropriately.
  • Administer immunizations according to best clinical practices and immunization guidelines prior to initiation of the corticosteroid regimen required before ELEVIDYS infusion.
  • Avoid administration of ELEVIDYS to patients with active infections.

Myocarditis

  • Acute, serious, life-threatening myocarditis and troponin-I elevations have been observed within 24 hours to more than 1 year following ELEVIDYS infusion.
  • If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes.
  • Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated, until results return to near baseline levels or stabilize.
  • More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath.
  • Advise patients to contact a physician immediately if they experience cardiac symptoms.

Infusion-related Reactions

  • Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate.
  • ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available.
  • Discontinue infusion for anaphylaxis. 

Immune-mediated Myositis

  • Immune-mediated myositis, including serious and life-threatening events, has occurred approximately 1 month following ELEVIDYS infusion. Signs and symptoms include severe muscle weakness, including dysphagia, dyspnea, dysphonia, and hypophonia.
  • Severe to life-threatening immune-mediated myositis has been reported in patients with deletions including portions of exons 1-17 and/or exons 59-71 of the DMD gene.
  • Regardless of genetic mutation, advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, dysphonia, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment based on patient's clinical presentation and medical history if these symptoms occur.

Preexisting Immunity against AAVrh74

  • In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies.
  • Perform baseline testing for the presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration.
  • ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers ≥1:400.

ADVERSE REACTIONS

  • The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased.

Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see full Prescribing Information, including Boxed Warning, and Medication Guide.